These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24022018)

  • 1. Evaluation of specific immune response in early P. aeruginosa infection in cystic fibrosis patients.
    Dolce D; Cariani L; Campana S; Ravenni N; Mergni G; Biffi A; Colombo C; Gagliardini R; Cirilli N; Manso E; Padoan R; Soncini E; Forte FR; D'Aprile A; Ratclif L; Amboni M; Casciaro R; Minicucci L; Borio T; Cosimi A; Vieni G; Zinnarello C; Fiscarelli E; Collura M; Pensabene T; Braggion C; Döring G; Taccetti G
    J Cyst Fibros; 2014 Jan; 13(1):116-7. PubMed ID: 24022018
    [No Abstract]   [Full Text] [Related]  

  • 2. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response.
    Hoiby N
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1974 Aug; 82(4):551-8. PubMed ID: 4213330
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.
    Mayer-Hamblett N; Kloster M; Rosenfeld M; Gibson RL; Retsch-Bogart GZ; Emerson J; Thompson V; Ramsey BW
    Clin Infect Dis; 2015 Sep; 61(5):707-15. PubMed ID: 25972024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystic fibrosis and pseudomonas infection.
    Lancet; 1983 Jul; 2(8344):257-8. PubMed ID: 6135081
    [No Abstract]   [Full Text] [Related]  

  • 5. Study of IgG antibodies to Pseudomonas aeruginosa in early cystic fibrosis infection.
    Giordano A; Magni A; Filadoro F; Graziani C; Quattrucci S; Cipriani P
    New Microbiol; 1998 Oct; 21(4):375-8. PubMed ID: 9812319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial Commentary: Pseudomonas aeruginosa Eradication: How Do We Measure Success?
    Zemanick ET; Laguna TA
    Clin Infect Dis; 2015 Sep; 61(5):716-8. PubMed ID: 25972023
    [No Abstract]   [Full Text] [Related]  

  • 7. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis.
    Bauernfeind A; Przyklenk B
    Behring Inst Mitt; 1997 Feb; (98):256-61. PubMed ID: 9382748
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anti-pseudomonas-specific precipitins as a marker of chronic infection in patients with cystic fibrosis].
    Castello D; Mari C; Visca A
    Minerva Pediatr; 1999 Mar; 51(3):47-51. PubMed ID: 10368566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa infection in cystic fibrosis. Distribution of B and T lymphocytes in relation to the humoral immune response.
    Hoiby N; Mathiesen L
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1974 Aug; 82(4):559-66. PubMed ID: 4213329
    [No Abstract]   [Full Text] [Related]  

  • 12. IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Pressler T
    APMIS Suppl; 1996; 66():1-41. PubMed ID: 8972694
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anti-Pseudomonas aeruginosa (Pa) antibiotic therapy and cystic fibrosis].
    Bellon G; Gilly R
    Rev Mal Respir; 1991; 8(2):263. PubMed ID: 1907014
    [No Abstract]   [Full Text] [Related]  

  • 14. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T
    Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis.
    Milagres LG; Castro TL; Garcia D; Cruz AC; Higa L; Folescu T; Marques EA
    Pediatr Pulmonol; 2009 Apr; 44(4):392-401. PubMed ID: 19283764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precipitating Pseudomonas aeruginosa antibodies and antimicrobial therapy in cystic fibrosis patients.
    Trancassini M; de Vito D; Cimino G; Antonelli M; Quattrucci S; Cipriani P
    Eur J Clin Microbiol Infect Dis; 1996 Apr; 15(4):309-12. PubMed ID: 8781882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods.
    Pressler T; Karpati F; Granström M; Knudsen PK; Lindblad A; Hjelte L; Olesen HV; Meyer P; Høiby N;
    J Cyst Fibros; 2009 Jan; 8(1):37-42. PubMed ID: 18835753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of Pseudomonas aeruginosa in cystic fibrosis.
    Eber E; Thalhammer GH; Zach MS
    Eur Respir J; 2006 Feb; 27(2):438-9. PubMed ID: 16452606
    [No Abstract]   [Full Text] [Related]  

  • 19. The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis.
    Buret A; Cripps AW
    Am Rev Respir Dis; 1993 Sep; 148(3):793-805. PubMed ID: 8368651
    [No Abstract]   [Full Text] [Related]  

  • 20. Pseudomonas aeruginosa and cystic fibrosis: intrastrain variability in relation to intensity of immune response and clinical outcome.
    Quentin R; Bollet C; Dayan A; Martin C; Goudeau A; De Micco P
    New Microbiol; 1993 Apr; 16(2):185-8. PubMed ID: 8510574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.